---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-120267"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:06:19.695194+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# VK2735 oral Phase 1 shows up to 8.2% weight loss; Phase 2 data support monthly maintenance dosing

## Summary
- Oral VK2735 achieved up to 8.2% mean weight loss from baseline (6.8% placebo-adjusted) at 28 days.
- 100% of subjects on 100 mg oral VK2735 reached ≥5% weight loss vs. 0% placebo; GI events mostly mild.
- Phase 2 VENTURE: 94% of weight loss maintained 4 weeks post-final dose; supports once-monthly dosing.
- 78% of prediabetic patients on VK2735 shifted to normoglycemic over 13 weeks vs. 29% on placebo.
- Oral Phase 2 to start by year-end 2024; injectable Phase 3 design to be discussed with FDA this quarter.

## SEC filing metadata
- accession: 0000950170-24-120267
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017024120267/0000950170-24-120267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017024120267/vktx-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-120267
- JSON: https://secwatch.observer/filing/0000950170-24-120267.json
- Plain text: https://secwatch.observer/filing/0000950170-24-120267.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.